Search

Displaying results 2061 - 2070 of 10000 in total
  1. Drug

    Sutimlimab

    go.drugbank.com/drugs/DB14996
    ApprovedInvestigational

    [L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116] … [A245159,L40114] In approximately 90% of cases, patients develop immunoglobulin M (IgM) autoantibodies towards the I antigen on erythrocytes - these antibodies react optimally at 4°C and are therefore

  2. Drug

    Plicamycin

    go.drugbank.com/drugs/DB06810
    ApprovedWithdrawn

    Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. … It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Anthrax vaccine

    go.drugbank.com/drugs/DB11003
    ApprovedInvestigational

    [L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas … [L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.

    Categories: Complex Mixtures
  4. Drug

    Penicillamine

    go.drugbank.com/drugs/DB00859
    ApprovedInvestigational

    It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Cevimeline

    go.drugbank.com/drugs/DB00185
    Approved

    Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3.

  6. Drug

    DaxibotulinumtoxinA

    go.drugbank.com/drugs/DB17929
    ApprovedInvestigational

    _C. botulinum_ is known to produce toxins that can cause botulism in humans. … DaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent.

  7. Drug

    Dabigatran etexilate

    go.drugbank.com/drugs/DB06695
    ApprovedInvestigational

    [A177463, A6970, L34675, L34680] Dabigatran etexilate may be used to decrease the risk of venous thromboembolic events in patients in whom anticoagulation therapy is indicated. … [A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022]

  8. Drug

    Viomycin

    go.drugbank.com/drugs/DB06827
    Approved

    These drugs bind RNA in bacterial ribosomes and inhibit protein synthesis. Viomycin was derived from the actinomycete _Streptomyces puniceus_.

  9. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. … [L14336] This accelerated approval is based on the rate and duration of therapeutic response observed in ongoing clinical trials and is contingent on the verification of these results in confirmatory trials

  10. Drug

    Doripenem

    go.drugbank.com/drugs/DB06211
    ApprovedWithdrawn

    In a clinical trial of doripenem treatment in ventilator associated pneumonia (vs. imipenem and cilastatin), it was found that doripenem carried an increased risk of death and lower clinical cure rates … , resulting in a premature termination of the trial.